Literature DB >> 7731761

Plasma copper and antioxidant status in Wilson's disease.

H Ogihara1, T Ogihara, M Miki, H Yasuda, M Mino.   

Abstract

It has been demonstrated that the level of serum copper unbound to ceruloplasmin (loosely bound copper) is increased in Wilson's disease, although the total serum copper concentration is usually low, reflecting a low ceruloplasmin level. To assess the contribution of free radical reactions catalyzed by nonceruloplasmin copper to the development of complications in this disease, we investigated copper and antioxidant status in four untreated patients who had hepatic dysfunction with or without hemolytic anemia and made a comparison with five patients controlled on penicillamine therapy and 19 age-matched healthy children. We found that loosely bound copper in plasma measured by the phenanthroline assay was detectable in three of four untreated patients with Wilson's disease, but was not detectable in the patients during therapy or in the healthy controls. Among the various antioxidants, the ascorbate and urate levels were markedly reduced before treatment (mean +/- SD, 23 +/- 16 microM for ascorbate and 90 +/- 59 microM for urate) compared with the values in the patients during treatment with penicillamine (67 +/- 19 and 302 +/- 78 microM, p < 0.05) and in control children (60 +/- 8 and 254 +/- 48 microM, p < 0.05). We also demonstrated that the plasma concentration of allantoin, an oxidation product of uric acid and a possible marker of radical generation in vivo, was markedly elevated in the untreated patients (11.0 +/- 1.8 versus 4.3 +/- 0.5 microM in patients on therapy and 6.5 +/- 0.8 microM in controls, p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731761     DOI: 10.1203/00006450-199502000-00016

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  14 in total

1.  Wilson's disease: A review of what we have learned.

Authors:  Kryssia Isabel Rodriguez-Castro; Francisco Javier Hevia-Urrutia; Giacomo Carlo Sturniolo
Journal:  World J Hepatol       Date:  2015-12-18

2.  Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors.

Authors:  Lenka Hasikova; Marketa Pavlikova; Hana Hulejova; Petr Kozlik; Kveta Kalikova; Aparna Mahajan; Martin Herrmann; Blanka Stiburkova; Jakub Zavada
Journal:  Rheumatol Int       Date:  2019-07-31       Impact factor: 2.631

3.  Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry.

Authors:  Adviye A Tolun; Haoyue Zhang; Dora Il'yasova; Judit Sztáray; Sarah P Young; David S Millington
Journal:  Anal Biochem       Date:  2010-03-31       Impact factor: 3.365

Review 4.  A review and current perspective on Wilson disease.

Authors:  Mallikarjun Patil; Keyur A Sheth; Adarsh C Krishnamurthy; Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2013-07-06

5.  Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms.

Authors:  Radan Bruha; Libor Vitek; Zdenek Marecek; Lenka Pospisilova; Sona Nevsimalova; Pavel Martasek; Jaromir Petrtyl; Petr Urbanek; Alena Jiraskova; Ivana Malikova; Martin Haluzik; Peter Ferenci
Journal:  J Inherit Metab Dis       Date:  2011-12-03       Impact factor: 4.982

Review 6.  Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention.

Authors:  Diana L Diesen; Paul C Kuo
Journal:  J Surg Res       Date:  2009-10-27       Impact factor: 2.192

7.  Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation.

Authors:  M Hermes-Lima; M S Gonçalves; R G Andrade
Journal:  Mol Cell Biochem       Date:  2001-12       Impact factor: 3.396

8.  Pyruvate released by astrocytes protects neurons from copper-catalyzed cysteine neurotoxicity.

Authors:  X F Wang; M S Cynader
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

9.  Metabolomics profiles of patients with Wilson disease reveal a distinct metabolic signature.

Authors:  Gaurav V Sarode; Kyoungmi Kim; Dorothy A Kieffer; Noreene M Shibata; Tomas Litwin; Anna Czlonkowska; Valentina Medici
Journal:  Metabolomics       Date:  2019-03-12       Impact factor: 4.290

10.  Randomized controlled open-label trial of vitamin E-bonded polysulfone dialyzer and erythropoiesis-stimulating agent response.

Authors:  Tsutomu Sanaka; Takahiro Mochizuki; Eriko Kinugasa; Eiji Kusano; Shigeru Ohwada; Tsutomu Kuno; Kenichiro Kojima; Shuzo Kobayashi; Minoru Satoh; Noriaki Shimada; Kazushi Nakao; Ryoichi Nakazawa; Hideki Nishimura; Eisei Noiri; Takashi Shigematsu; Tadashi Tomo; Teiryo Maeda
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.